News Hub | News Direct

All Industries


Article thumbnail News Release

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Benzinga

By Faith Ashmore, Benzinga A recent cancer study showed that the incidence rates of early-onset cancer “increased substantially” from 2010 to 2019. Breast cancer had the highest number of incident cases, and gastrointestinal cancers had the fastest-growing incidence rates among all early-onset cancers. The National Cancer Institute reports that colorectal cancer has become the leading cause of cancer-related deaths for Americans aged 20 to 59 years old. Doctors are expecting that in 2024, there will be more than 2 million new cases of cancer; this would be the first year the U.S. would cross that threshold, marking almost 5,500 cancer diagnoses a day. The increasing cancer incidence, especially among young people, is a big cause for concern in the medical community. Specifically, there is an increase in pancreatic cancer, which is expected to become the second-highest cause of cancer-associated deaths in 2030 in the U.S. Fortunately, fatality rates from cancer have steadily been on the decline for the past 30 years. This is largely due to better detection systems and advancements in treatment. Theriva Biologics (AMEX: TOVX) is one of the biotech companies that is helping push the envelope in cancer treatment. The company specializes in developing oncolytic viruses that are unique and highly differentiated. These viruses have been optimized for systemic administration and are designed to treat various types of cancer and make other cancer therapies more effective. They are optimized to be administered in combination with chemotherapy and immunotherapies, increasing access to the tumor and exposing the tumor to the immune system. The company’s lead drug candidate is VCN-01, which is a uniquely engineered human adenovirus 5. VCN-01 also expresses a protein named hyaluronidase that degrades the dense matrix surrounding human tumors, and this helps the action of chemotherapy and immunotherapies. The phase 1 clinical trials of VCN-01 have shown promising results for the treatment of several additional indications such as pancreatic cancer, retinoblastoma, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) in combination with chemotherapy and immunotherapies. The company's innovative Albumin Shield™ platform and oncolytic virus discovery engine have enabled the development of a distinct product pipeline that holds promise in the fight against cancer. Currently, the company is conducting a phase 2b clinical trial of its VCN-01 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. Theriva Biologics is on track to complete enrollment into the VIRAGE Study by the first half of 2024. In the first quarter of 2024, a Drug Monitoring Committee (DMC) conducted a thorough safety review of VCN-01, ensuring that the drug meets the necessary criteria for continued development. By the second half of 2024, Theriva Biologics aims to perform an interim analysis of the data obtained from the VIRAGE Study. Theriva Biologics And Its Potential Markets By The Numbers The pancreatic cancer market’s size was estimated at $2.2 billion in 2022, and it's expected to grow at a CAGR of 13.6% between 2023 and 2032, reaching approximately $7.91 billion by 2032. Theriva Biologics seems well-positioned to excel in this space with its innovative VCN-01 drug candidate, with the potential to also serve other multi-billion dollar markets – such as head and neck cancer drugs, set to surpass $2.99 billion by 2030. Theriva Biologics reported $31.6 million in cash and short-term investment for Q3 2023. The company also increased research expenses to $4 million from $2.6 million a year ago while decreasing general and administrative expenses by 91% y-o-y. The company narrowed its net loss for the quarter from $4.49 million in Q3 2022 to $3.3 million in Q3 2023, and the basic loss per share for the quarter was $0.19 compared to $0.3 a year ago. Theriva Biologics currently has a market capitalization of about $8 million. The clinical-stage company’s innovative drug research might present a novel solution to extend the lives of those suffering from the deadliest of cancers, providing patients with new hope and improved outcomes. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:25 AM Eastern Standard Time

Image
Article thumbnail News Release

OLB Group is Making Omnicommerce and Wireless Plans Accessible to the Underbanked and Revolutionizing Payments for Businesses

Benzinga

By Faith Ashmore, Benzinga Omnicommerce is an integrated "all-channel" retail approach that provides consistent, seamless and personalized customer experiences, ultimately leading to secure and frictionless payments. It encompasses meeting customers where they are, whether through physical stores, online platforms, social media or other digital spaces. By adopting an omnichannel strategy, businesses can create a unified brand presence and deliver a smooth consumer experience across multiple channels. As technology continues to advance and consumer expectations evolve, the omnicommerce industry will continue to grow and play a significant role in shaping the future of the retail industry. In 2022, the global market size of retail omnichannel commerce platforms was $8.1 billion, and is projected to grow at a CAGR of 16.6% from 2022-2030. Businesses today are investing more in developing omnicommerce solutions, such as mobile websites, apps, personalized email marketing and social media integration. However, not all businesses have the technology to adopt this approach and have to look to third-party technology companies for help. That’s where companies like OLB Group (NASDAQ: OLB) come into play to make omnicommerce more accessible. OLB offers a comprehensive suite of products and services, catering to the needs of small and medium-sized enterprises (SMEs) as well as larger organizations. OLB's flagship product, OmniSoft, is a cloud-based e-commerce platform that enables businesses to easily establish an online presence, manage and track their sales and accept payments securely. In June 2023, OLB acquired a controlling interest in black011.com, which encompasses Black Wireless and Mango Mobile, and is beginning to contribute to revenues. These strategic moves enabled the company to offer one Point of Sales (POS) system to customers so they can purchase products and seamlessly reload mobile phone minutes.. OLB is in the process of rebranding these platforms and integrating them into the OLB Payment Platform and ECO Payment system. Ultimately, these acquisitions enable OLB to focus on the rapidly growing underbanked communities. As of 2022, a market study revealed that approximately 13% of American adults were underbanked, a new market that OLB has identified as underserved. Increased accessibility can dramatically help these communities and provide bodegas and convenience stores with a new service to their customers. In November, the company reported a wider-than-expected quarterly loss, but an often overlooked accounting technicality is that the loss was largely due to non-cash depreciation “expense”. However, to underscore the confidence in the company’s future, Chairman and CEO Ronny Yakov acquired a total of 784,212 shares and Vice President Patrick Smith purchased a total of 392,106 shares at an average price of $0.77. OLB also provides various payment processing solutions, such as point-of-sale systems, mobile payment applications and virtual wallets – allowing businesses to accept payments from customers through multiple channels. To date, the company has worked with 10,500 merchants worldwide and secured over 28.5 million transactions annually in over 130 different industries. OLB prides itself on being a comprehensive single solution with over 15 years of experience. The company runs on the SaaS model with pay-as-you-go options, making its platform more accessible to businesses of all sizes. With a modest market capitalization of around $13 million and an annual revenue run rate of over $30 million (one of the lowest Price to Sales ratios of 0.3 times sales vs. a peer average of 1 x sales), OLB Group may represent an opportunity for investors interested in participating in the broadening out of the payments industry to include more of the underbanked. The emergence of omnicommerce reflects the next evolution in e-commerce for both businesses and customers alike and the growing recognition of payments as a cornerstone in every customer journey. With the convenience and accessibility of online shopping, customers now expect a seamless and personalized shopping experience across various touchpoints. With a commitment to empowering businesses with efficient and secure payment solutions, OLB is establishing itself as a trusted provider in the payments industry. Featured photo by Mark König on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:20 AM Eastern Standard Time

Image
Article thumbnail News Release

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Benzinga

By Meg Flippin, Benzinga MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy to fight advanced non-small cell lung cancer or NSCLC. NSCLC is a disease in which cancer cells form in the tissues of the lung. It’s the most common form of lung cancer in the U.S., accounting for 81% of lung cancer diagnoses. The five-year survival rate for this type of cancer is 28%. THIO targets and compromises the function of telomeres, which play a key role in helping cancer cells live and spread. Telomeres are made from DNA sequences and proteins and sit at the end of chromosomes, capping and protecting them in the cell division progress. Telomeres can be regenerated with the support of telomerase, an enzyme present in the early stages of growth and development in humans and in very few cells of adults. Telomerase is present in nearly all cancers and is expressed in 80% of NSCLC tumors. Evaluating The Effectiveness THIO is recognized by telomerase, leading to the uncapping of telomeres and thus resulting in rapid tumor cell death. THIO induces telomerase-dependent telomeric DNA modification, DNA damage responses and selective cancer cell death. The phase 2 THIO-101 go-to-market clinical trial is designed to evaluate THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with NSCLC. In preclinical models in vivo, MAIA demonstrated that low doses of THIO followed by anti-PD-L1 or anti-PD1 therapy completely eliminated advanced tumors and produced cancer cell-specific memory to activate the immune system against the cancer cells after extended periods with no need for additional treatment. Enrollment Reached Ahead Of Schedule Earlier in February, the trial reached its enrollment target of 41 patients for the 180 mg dose. Initially, the trial was designed to test three dose levels but following the selection of 180 mg/cycle as the optimal dose in December all patients were enrolled at that dose level and trial enrollment was completed ahead of schedule, the company said in a press release. “Enrollment in our Phase 2 THIO-101 trial has been strong from the start. With excellent results across all doses and our selection of the optimal dose in December 2023, we enrolled the necessary number of patients in the Simon 2-stage design to achieve our trial endpoints earlier than expected,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer when announcing the enrollment results. “THIO-101 preliminary data has demonstrated unprecedented rates of disease control and response to date, and we look forward to the long-term efficacy results as we continue to monitor the enrolled patients in the upcoming months.” THIO Well Tolerated The main objectives of the trial are to evaluate the safety, tolerability and preliminary clinical efficacy of THIO in patients with advanced NSCLC who have experienced disease progression or relapse after initial treatments with an immune CPI alone or in combination with chemotherapy. THIO is currently being developed as a second or later line of treatment for NSCLC patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. MAIA Biotechnology said treatment with THIO followed by cemiplimab (Libtayo®) followed by THIO has been generally well tolerated to date in a heavily pre-treated population. “As the only direct telomere targeting agent currently undergoing clinical development in the field of cancer, we believe THIO holds a time-to-market advantage and strong potential to become a new standard of care for NSCLC,” said Vitoc. While THIO is currently being tested for NSCLC, telomerase is present in 85% to 95% of human cancers and contributes to the proliferation and reproductive immortality of cancer cells. As a result, the company is studying THIO in models of several tumor types with active telomerase, including rate indications in liver, colorectal and brain cancers. That could result in further use cases for MAIA’s lead treatment. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:15 AM Eastern Standard Time

Image
Article thumbnail News Release

TeamBuilder's Innovative Staff Scheduling Solution Recognized in KLAS Insights Report

TeamBuilder

TeamBuilder, an innovative workforce management solution, has been featured in the latest insights report by KLAS, a renowned healthcare research firm. The report, titled "Emerging Insights Case Study on Workforce Management and Predictive Staff Scheduling through a Digital Platform," highlights TeamBuilder's pioneering approach to staff scheduling and its positive impact on healthcare organizations. Staff scheduling in healthcare has a unique set of challenges that can be exacerbated by provider volume and manual processes for clinical workflow management. These challenges can lead to problematic patient care and poor provider and staff experiences. The TeamBuilder solution, built specifically for ambulatory care, is intended to alleviate organizational pain points around staff scheduling by assessing the needs of day-to-day operations and offering predictive staff scheduling. Key findings from the case study include: Improved Operational Efficiency: TeamBuilder's predictive staff scheduling reduces administrative burdens and streamlines day-to-day operations, allowing healthcare organizations to focus on delivering quality patient care. Enhanced Staff Experience: Users of TeamBuilder's platform reported positive experiences, citing the ease of use, real-time notifications, and centralized communication features as key strengths. Positive Organizational Outcomes: TeamBuilder's digital schedule and recommendation engine drive positive outcomes, including workforce management optimization, reduced staffing costs, and improved visibility into staffing utilization across multiple sites. "What's been done traditionally around using staffing ratios often leads to chronic overstaffing and understaffing because they don't account for nuances like shifting patient volume, provider workflow and sites that answer phones," said David Howard, CEO and Founder of TeamBuilder. "What we've been able to do with TeamBuilder is to use data science to consume all of the nuances of a clinic's operating model and provide managers with the optimal schedule each week. No more paper. No more guessing." To read the full report, visit TeamBuilder — News. About TeamBuilder: TeamBuilder is a predictive staff scheduling platform built specifically for ambulatory care. Contact Details TeamBuilder Media info@teambuilder.io Company Website https://teambuilder.io/

February 29, 2024 08:00 AM Eastern Standard Time

Article thumbnail News Release

Roll1ng Thund3rz Unveils Web3War® v3.0: Pioneering the Future of Gaming with Skill2Earn Dynamics

Roll1ng

In a monumental leap forward for the gaming industry, Roll1ng Thund3rz (RTz), the pioneering Web3 gaming company, proudly announces the launch of Web3War® v3.0. This latest iteration introduces game-changing features, with Skill2Earn taking center stage in Season 1, accompanied by the Ranked Matches and an enticing Season Pass. Skill-to-Earn: A Paradigm Shift in Gaming Dynamics Web3War®’s version 3.0 is not merely an update; it’s a major transformative experience for gamers worldwide. The implementation of Skill2Earn in Season 1 empowers players to monetize their in-game prowess. The Season Pass, a cornerstone of this release, can be acquired by staking $FPS tokens, establishing a direct link between player achievements and real-world rewards. Valentin Cobelea, CTO and co-founder of Roll1ng Thund3rz, emphasizes the significance of Skill2Earn: “We believe in creating a gaming ecosystem where players are not just participants but contributors. Skill2Earn is a testament to our commitment to rewarding the dedication, talent and skills of our gaming community, ushering in a new era of interactive and rewarding gameplay.” Unlocking a World of Possibilities: Season 1 & Season Pass Unveiled Elevating the gaming experience to unprecedented heights, Roll1ng Thund3rz introduces the Season Pass, an intricate tapestry of 25 items that promise to immerse players in a world of digital ownership. By staking $FPS tokens, players gain access to this treasure trove, a series of items spread across 25 levels that unfold with each match played by gaining also Season XP. Delving into this trove, 15 items take the form of coveted skin NFTs, transforming the appearance of in-game weaponry with unparalleled style and rarity. Importantly, the Season Pass extends an inclusive touch, offering 2 of the 15 premium skin NFTs to all players, even those without the pass. Players must embark on regular or ranked matches or both, earning Season XP with every move, to unlock each level and claim their piece of the coveted Season Pass bounty. This dynamic system not only rewards skill and dedication but also crafts a unique journey for players, where progression becomes a tangible and visually stunning testament to their prowess within the immersive world of Web3War®. Ranked Matches as Team-Based Showdowns Web3War® version 3.0 introduces Ranked Matches across the game’s 12 meticulously crafted maps, providing players with diverse environments for intense team-based competitions. Whether engaging in 1v1, 2v2, 3v3, or 4v4 battles, participants can enter by paying a fixed access fee in $FPS tokens. The winning team claims an impressive 88% of the total access pool, adding a layer of competitiveness and stakes to every match; 2% being burned and the 10% going to RTz for development support. Matt Dyer Reflects on The $FPS Token Listing Matt Dyer, the CEO of Roll1ng Thund3rz and Zilliqa blockchain, remarks on this highly important achievement: “The demand for $FPS tokens reflects the community’s confidence in Web3War®’s potential and the widespread adoption of blockchain gaming. Once more, we have demonstrated our unwavering commitment to fostering Web3 gaming adoption.” FUS1ON Gaming Hub®: Revolutionizing Functionality and Web3War®’s Aesthetics FUS1ON® Hub, the heart of the game’s digital marketplace, unveils a stellar update of its own. Boasting an extensive collection of more than 10000 new skin NFTs, FUS1ON Gaming Hub® takes customization to a whole new level, allowing players to express their individuality with unrivaled style. This update introduces a slew of features, including token swapping and seamless token transfers between player wallets. Navigating the Mark3t, FUS1ON Gaming Hub®’s marketplace for skin NFTs, has never been easier, thanks to the addition of Collections, ensuring a streamlined and immersive experience for all Web3War® enthusiasts. FUS1ON Gaming Hub® remains at the forefront of innovation, enhancing both aesthetics and functionality within the expansive universe of Web3War® – which can easily be reached not only on the Microsoft Store here, but also directly online at www.mark3t.store and www.fus1on.online. Charting the Future of Gaming Roll1ng Thund3rz has not only elevated Web3War® to new heights but has also set the stage for the future of web3 gaming with this major release which also well impacted the FUS1ON Gaming Hub® with the additional layers of technologies and security. As Skill2Earn takes center stage, players become active participants in an ecosystem that values skill, competition, and community engagement. Web3War® v3.0 is more than a game; it’s a testament to the studio’s commitment to pushing boundaries and redefining the gaming experience in its very own ecosystem. As the gaming community eagerly dives into the immersive world of Web3War® v3.0 as a leading game in the FUS1ON Gaming Hub®, the collaboration of Skill2Earn mechanics, Season Pass incentives, and the strategic use of $FPS token underscores Roll1ng Thund3rz’s position as a pioneer in the rapidly evolving landscape of web3 gaming. About Roll1ng Thund3rz Roll1ng Thund3rz is an integrated entertainment company that is part of the Zilliqa Group, building products for gamers, by gamers, using Web3 and blockchain technologies. With a focus on creating quality games and engaging experiences, Roll1ng Thund3rz is dedicated to advancing gaming by leveraging vanguard technologies to shape the future of the industry. About Web3War® Web3War® is the first-person shooter crafted by Roll1ng Thund3rz and secured by Zilliqa. W3W is a multiplayer, free-to-play, seasonal content-oriented FPS game that prioritizes fun and high-quality gameplay above all else. Contact Details Roll1ng Thund3rz Team Marketing contact@rtz.gg

February 29, 2024 06:35 AM Eastern Standard Time

Image
Article thumbnail News Release

Bitget Announces Listing of Portal: Revolutionizing the Web3 Gaming Landscape

Bitget

Bitget, the leading cryptocurrency exchange and Web3 platform, is thrilled to announce the listing of Portal, a groundbreaking platform set to transform the Web3 gaming experience, in its Innovation and GameFi Zone. Portal is designed to simplify the discovery and engagement with Web3 games, providing a seamless, frictionless journey for mainstream gamers into the vast network of blockchain-based gaming. Portal's innovative platform enables gamers to access and play games across all chains through a single account layer, eliminating the need for bridging, swapping, or purchasing additional tokens. This development marks a significant milestone in the evolution of Web3 gaming, making it more accessible and enjoyable for gamers worldwide. The native utility and universal gaming token of the Portal ecosystem, $PORTAL, plays a central role in facilitating various functions within this expansive gaming landscape. Portal's cross-chain gaming ecosystem is a first-of-its-kind, connecting games across every blockchain and leveraging Portal’s multi-chain token and gaming infrastructure to offer an unprecedented gaming experience. Gracy Chen, Managing Director of Bitget, commented on the listing, "Bitget is always on the lookout for innovative ways to support the development of diverse blockchains and ecosystems. Bitget's decision to list Portal underscores its dedication to fostering innovation and expanding its offerings to include unique and high-quality projects. This collaboration signifies a pivotal step towards bridging the gap between traditional gaming and the burgeoning world of Web3, paving the way for a new era of digital entertainment." Bitget has בonsistently expanded its market presence in both spot and derivatives trading within centralized exchanges. In 2023 alone, the platform introduced over 350 new listings, showcasing its dedication to diversifying the digital assets available in its spot market. Meanwhile, Bitget Wallet supports over 100 mainnets and 250,000+ tokens. Its on-chain trading function Bitget Swap enables cross-chain trading between 40 mainnets. For more information, users can visit: https://www.bitget.com/support/articles/12560603805760 About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 20 million users in 100+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, swap, NFT Marketplace, DApp browser, and more. Bitget inspires individuals to embrace crypto through collaborations with credible partners, including legendary Argentinian footballer Lionel Messi and official eSports events organizer PGL. For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet Contact Details Rachel Cheung media@bitget.com Company Website https://www.bitget.com/

February 29, 2024 06:26 AM Eastern Standard Time

Image
Article thumbnail News Release

LTO Network makes their Layer-1 blockchain available for the fight against counterfeit goods

LTO Network

Scantrust and LTO Network Partnering for Secure, Transparent items. Scantrust's innovative Secure QR codes, a well-known and proven tool against counterfeiting, can now be used in conjunction with LTO Network's secure, transparent blockchain technology. This allows organizations that depend on critical documents and high-value, luxury goods to have additional options to establish and maintain a new level of trust and accountability. Any item with Scantrust Secure QR codes can have their authenticity verified in a matter of seconds using a mobile phone. With the LTO Network, an additional, immutable digital audit trail for information can be added, creating a secure data anchor for government certificates, product and safety certifications, diamond certificates, warranty cards for luxury goods (e.g. watches) and any other high-value items. The LTO Network blockchain also supports a new way to track supply chain information. By integrating blockchain for enhanced transparency and immutability, counterfeiters are blocked from easily faking the origin of the counterfeit items they sell. In an industry plagued by a $500 billion counterfeiting problem, these tools represent a significant step forward in protecting businesses and safeguarding consumers. The option to integrate LTO Network’s technology with Scantrust Secure QR codes is part of a vision for a future where trust is built into the very fabric of our transactions and trades. For Scantrust, it's an opportunity to expand their reach and further their mission of document security. For LTO Network, it's about adding a powerful document security layer to their suite of privacy-focused solutions, offering their clients a comprehensive package for building trust in today's digital world. About LTO Network LTO Network is a privacy-aware Layer-1 blockchain for Real World Assets, Data Security and Identity solutions. The platform is designed for business process efficiency and security. It combines a public layer for transparency and a private layer for data security, ensuring GDPR and MiCA compliance. This dual-layer approach makes it ideal for enterprises requiring data privacy and regulatory adherence. LTO Network also offers tokenization of RWAs through their Ownables technology, enabling assets to be brought on-chain and allowing them to interact with the world of DeFi and Web3. LTO Network's KYC services help maintain compliance with anti-money laundering laws as well as offering proof of humanity services to protect Web3 and DeFi platforms from bots. ltonetwork.com About Scantrust Scantrust helps manage and resolve counterfeit product problems, address supply chain traceability and inventory management challenges, and provides tools for regulatory compliance related to product data requirements. Maintain and build your brand's integrity, gather detailed consumer insights, and simplify your traceability regulatory compliance efforts. Learn more at www.scantrust.com Contact Details LTO Network BV Shawn Naderi shawn@ltonetwork.com

February 29, 2024 06:13 AM Eastern Standard Time

Video Image
Article thumbnail News Release

BinaryX IGO to list Project Matthew: Build A Space City With ERC-404 NFTs

BinaryX

BinaryX announced today the highly anticipated launch of their first Initial Game Offering (IGO) of the year, Project Matthew. Project Matthew is a space-building simulation game where players get to experience what it is like to work in space, officially known as the planet Matthew in the game. In the game, players work not as astronauts, but as builders and engineers that make space livable for a new civilization. Own ERC-404 NFT tokens and exchange for in-game land Players have the opportunity to own fractionalized ERC-404 NFTs that can be converted to ownership of in-game land, weapons, and other materials. ERC-404 tokens provide users with ample liquidity while also opening up different possibilities for their future ownership, including shared ownership of land, buildings and resources. The game, with its innovative use of ERC-404 tokens, is expected to promote collaboration, a sense of community, and open the game to a wider audience without compromising the exclusivity of in-game NFT ownership. The Story of Project Matthew: A Space Building Simulator Humans discover a not-so-distant planet called Matthew with the potential to house living beings. As pioneers of space living, players will have the opportunity to design and manage their very own industrial plants, mine for resources, build robots that can help to work in the plants as well as fight other intergalactical forces, and construct their very own space city from the ground up. Lead A Virtual Army Players can recruit a robot army with different skills and abilities, and challenge enemies on the battlefield to earn massive rewards. The battlefield is divided into different levels of difficulties. The more difficult the level, the greater the rewards. Explore Space Exploration is one of the primary ways to obtain rewards and resources in Project Matthew. The gameplay features a collection of neighboring and faraway planets waiting to be explored. “Project Matthew is our first IGO project for the first half of 2024. We wanted our players to have the opportunity to experience living and working in space, and this game is the first ever simulation game in the Web3 space to offer a semi-realistic experience for that”, said Julio, Head of Investments at BinaryX. “We’re excited and geared up to support more quality games like Project Matthew on our IGO platform in 2024.” Users can participate in the IGO here About BinaryX BinaryX is a leading Web3 gaming platform dedicated to creating immersive and engaging gaming experiences like Ai Hero and Pancake Mayor, Built on the BSC Chain, BinaryX leverages the latest technologies in blockchain and AI to provide over 100k players with unique opportunities to own in-game assets, participate in decision-making processes, and experience the true potential of Web3 gaming. For more details and information about BinaryX, users can visit www.binaryx.pro Users can stay update on social media: BinaryX | Twitter | Discord | Telegram | YouTube | Medium Contact Details BinaryX Kora marketing@binaryx.pro

February 29, 2024 05:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Memeinator Smashes Past the $5m Mark

Memeinator

Memeinator is currently sitting at over $5.2 million in presale buys. Sustained presale action follows the continued rollout of roadmap promises. Earlier this month, Memeinator announced a partnership with award-winning game studio Red Apple Tech for the development of the Meme Warfare game. Head of Product, Marco Tonetti, said: “The fantastic performance in the presale means the market knows what we’re about: we care about delivering a fun project with genuine longevity and none of the derivative nonsense that’s so common in the space. We’re continuing to develop Memeinator to give our audience the best experience possible, and our partnership with Red Apple is just one part of that.” Memeinator (MMTR) is available to buy on the official site. Memeinator’s Mission Memeinator’s mission is simple: to make meme coins fun and rewarding again while fighting back against the half-baked projects that have come to define the sector. This fight is embodied in Meme Warfare, an AI-infused game where, playing as the Memeinator, players can battle against inferior meme coins. These coins are fed into the game by an AI that scans the community’s suggestions for meme coins worthy of destruction. Memeinator intends to reach a $1 billion market cap as it becomes the world’s top meme coin, aiming to leverage its marketing efforts to the fullest in pursuit of this goal. Inside MMTR’s Push To $5 Million The project’s adherence to roadmap promises is likely a significant driver behind recent growth. Currently in Phase 1 of its roadmap, Memeinator is on schedule, with Meme Warfare under development and the team now fully in place. Phase 2 of Memeinator’s roadmap includes NFTs, staking, and influencer campaigns. Wider market conditions may have also played a role in the $5 million figure being reached so soon. Bitcoin breached $60k recently for the first time since 2021, which for many represents a confirmation of a full-blown bull market. There looks to be more good news on the horizon, too. Ethereum ETFs could hit the market as soon as May, and the Bitcoin halving looms in April, setting the scene for a market-wide rally. As capital flows into crypto, it’s likely that an altcoin season will kick off, with some analysts believing this has already begun. Memeinator is perfectly positioned to ride the wave of an altcoin gold rush, bringing its $1 billion market cap target very much into view. The Memeinator presale has now entered Stage 16, putting MMTR at $0.0233. The price will rise to $0.0246 when Stage 17 begins. About Memeinator Memeinator is the antidote to the hundreds of throwaway meme coins that lack any legitimate utility. With its deflationary token, engaged community, expertly crafted NFT collection, and AI-powered video game, it offers real innovation instead of just hype. Its purpose is to eclipse its rival meme coins. And, on the way, to deliver strong returns to its community via both trading its MMTR coin and staking before smashing the $1 billion market cap. For more information, users can visit Memeinator's website. Website | Whitepaper | Socials Contact Details Memeinator Memeinator Team pr@memeinator.com

February 29, 2024 05:00 AM Eastern Standard Time

Image
1 ... 389390391392393 ... 3766